Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of Curability.
Clin Lymphoma Myeloma Leuk
September 2024
Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece. Electronic address:
Article Synopsis
- Multiple myeloma is a complex type of blood cancer, and Dr. Raymond Alexanian has made significant contributions to its research and treatment over his nearly 50-year career.
- He developed the MP (melphalan-prednisone) regimen, which became a standard treatment, and collaborated with Dr. Bart Barlogie on the VAD (vincristine, doxorubicin, and dexamethasone) regimen to improve outcomes for difficult-to-treat cases.
- Dr. Alexanian also helped establish high-dose melphalan with autologous stem cell transplantation and evaluated new drugs like thalidomide and bortezomib, leaving a lasting impact on both patient care and the quest for a
Isolated central nervous system (CNS) relapse of multiple myeloma 11 years after autologous stem cell transplantation: a case report.
AME Case Rep
September 2024
Hemato-oncologic specialties center (CEDEHO), Spanish Hospital of Mexico, Mexico City, Mexico.
Background: Multiple myeloma (MM) relapse in the central nervous system (CNS) confers an adverse prognosis, usually occurring in a short period after stem cell transplant and with a short overall survival. Isolated CNS relapse is so rare that there is no current standard treatment.
Case Description: We present a 59-year-old male with an isolated CNS MM relapse, who had received autologous stem-cell transplant (ASCT) and thalidomide maintenance 11 years prior.
[Diagnosis and management of POEMS syndrome].
Rinsho Ketsueki
October 2024
Department of Hematology, International University of Health and Welfare.
Article Synopsis
- - POEMS syndrome is a rare plasma cell neoplasm that causes symptoms like neuropathy, enlarged organs, fluid buildup, skin issues, bone lesions, and specific abnormal proteins in the blood.
- - The causes of POEMS syndrome are not well understood, and it can be confused with chronic inflammatory demyelinating polyneuropathy (CIDP), making it crucial to recognize its unique indicators.
- - Treatment typically involves newer myeloma drugs like thalidomide, lenalidomide, and bortezomib, often followed by high-dose chemotherapy and stem cell transplant for younger patients, with ongoing research needed for managing relapses.
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol
November 2024
Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Article Synopsis
- The study evaluates the effectiveness of a treatment regimen (ixazomib, thalidomide, and dexamethasone) followed by maintenance with ixazomib after salvage autologous hematopoietic stem-cell transplantation (HSCT) for patients with relapsed multiple myeloma, compared to observation.
- Conducted as part of a larger trial (Myeloma XII) across 79 UK hospitals, it involved patients aged 18+ with measurable disease and certain health criteria, randomized into two treatment groups.
- The primary measurement for effectiveness was progression-free survival, with safety assessments also being conducted, and a total of 206 patients participated in this phase of the trial.
Induction prior to autologous haematopoietic cell transplantation in multiple myeloma.
Br J Haematol
December 2024
Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Centre de Recherche Saint-Antoine INSERM UMRs938, Sorbonne Université, Paris, France.
Induction chemotherapy followed by autologous haematopoietic cell transplantation and post-transplant therapy (including maintenance therapy with or without prior consolidation) is still considered as the standard of care for newly diagnosed young and fit multiple myeloma patients. Over the last years, superiority of quadruplet regimens for induction was established, with the addition of an anti-CD38 monoclonal antibody to triplet regimen including a proteasome inhibitor, an IMiD (thalidomide or lenalidomide) or cyclophosphamide, and dexamethasone. Given quadruplet induction regimens are associated with deep response, including a high-rate of sustained measurable residual disease negativity in a significant proportion of patients, they are now recommended for induction chemotherapy when available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!